Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-21
2007-08-21
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S452000
Reexamination Certificate
active
11052489
ABSTRACT:
A β crystalline form of the compound of formula (I):characterized by its powder X-ray diffraction data.Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.
REFERENCES:
patent: 4914214 (1990-04-01), Vincent et al.
patent: 6653336 (2003-11-01), Guez et al.
patent: 2004/0248817 (2004-12-01), Pfeiffer et al.
patent: 2005/0059609 (2005-03-01), Pfeiffer et al.
patent: 0308341 (1989-03-01), None
patent: 2771010 (1999-05-01), None
Brittain “polymorphism in pharmaceutical solids” marcel Dekker, p. 1,2, 178-179, 185, 219 and 236 (1999).
US Pharmacopia #23, national formulary #18, p. 1843-1844 (1995).
A. Maureen Rouhi, Chemical & Engineering News, Feb. 24, 2003, pp. 32-35.
Brittain “Polymorphism in Pharmaceutical Solids” Marcel Dekker, p. 332, 334, 335, 338-341, (1999).
Beilles Stéphane
Coquerel Gerard
Ginot Yves-Michel
Pfeiffer Bruno
Anderson Rebecca
Hueschen and Sage
Les Laboratoires Servier
LandOfFree
β crystalline form of perindopril tert-butylamine salt does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β crystalline form of perindopril tert-butylamine salt, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β crystalline form of perindopril tert-butylamine salt will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3890082